In the industry's words – Swedish Medtech
This article was originally published in Clinica
Industry association Swedish Medtech is currently celebrating its 40th anniversary. Chief executive Anna Lefevre Skjöldebrand speaks here about the challenges faced by the association, whose members generate around 90% of Sweden's medtech market turnover, and its expectations for the future
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.